Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Short-term Investments (2020 - 2026)

Design Therapeutics' Short-term Investments history spans 2 years, with the latest figure at $85.5 million for Q4 2021.

  • On a quarterly basis, Short-term Investments rose 181804.26% to $85.5 million in Q4 2021 year-over-year; TTM through Dec 2021 was $85.5 million, a 181804.26% increase, with the full-year FY2021 number at $85.5 million, up 181804.26% from a year prior.
  • Short-term Investments hit $85.5 million in Q4 2021 for Design Therapeutics, up from $104000.0 in the prior quarter.
  • Over the last five years, Short-term Investments for DSGN hit a ceiling of $85.5 million in Q4 2021 and a floor of $47000.0 in Q4 2020.